Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 9, 2015, Pages 987-992

  Wurz, Ryan P ^a   Pettus, Liping H ^a   Ashton, Kate ^a   Brown, James ^a   Chen, Jian Jeffrey ^a   Herberich, Brad ^a   Hong, Fang Tsao ^a   Hu Harrington, Essa ^a   Nguyen, Tom ^a   St Jean, David J ^a   Tadesse, Seifu ^a   Bauer, David ^a   Kubryk, Michele ^a   Zhan, Jinghui ^a   Cooke, Keegan ^a   Mitchell, Petia ^a   Andrews, Kristin L ^a   Hsieh, Faye ^b   Hickman, Dean ^b   Kalyanaraman, Nataraj ^b   Wu, Tian ^a   Reid, Darren L ^a   Lobenhofer, Edward K ^a   Andrews, Dina A ^a   Everds, Nancy ^a   Guzman, Roberto ^a   Parsons, Andrew T ^a   Hedley, Simon J ^b   Tedrow, Jason ^b   Thiel, Oliver R ^b   Potter, Matthew ^b   Radinsky, Robert ^a   Beltran, Pedro J ^a   Tasker, Andrew S ^a   more..

^a Medicinal Chemistry ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

EGFR; EGFR T790M mutant; Epidermal growth factor receptor; irreversible inhibitor; kinase inhibitor; nonsmall cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; OXOPYRIDO[2,3 D]PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; LUNG CANCER CELL LINE; MALE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

EID: 84941564103     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00193     Document Type: Article

References (35)

1. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 2007, 7, 169-181 10.1038/nrc2088
2. Ohashi, K.; Maruvka, Y. E.; Michor, F.; Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J. Clin. Oncol. 2013, 31, 1070-1080 10.1200/JCO.2012.43.3912
3. Chong, C. R.; Jänne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer Nat. Med. 2013, 19, 1389-1400 10.1038/nm.3388
4. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks J. Med. Chem. 2012, 55, 6243-6262 10.1021/jm3003203
5. Potashman, M. H.; Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design J. Med. Chem. 2009, 52, 1231-1246 10.1021/jm8008597
6. Ou, S.-H. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence Crit. Rev. Onc./Hematol. 2012, 83, 407-421 10.1016/j.critrevonc.2011.11.010
7. Schwartz, P. A.; Kuzmic, P.; Solowiej, J.; Bergqvist, S.; Bolanos, B.; Almaden, C.; Nagata, A.; Ryan, K.; Feng, J.; Dalvie, D.; Kath, J. C.; Xu, M.; Wani, R.; Murray, B. W. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 173-178 10.1073/pnas.1313733111
8. Singh, J.; Evans, E.; Hagel, M.; Labinski, M.; Dubrovskiy, A.; Nacht, M.; Petter, R. C.; Prasad, A.; Sheets, M.; St. Martin, T.; Sjin, R. T. T.; Westlin, W.; Zhu, Z. Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance MedChemComm 2012, 3, 780-783 10.1039/c2md20017a
9. For an example of second generation inhibitors, see: Xia, G.; Chen, W.; Zhang, J.; Shao, J.; Zhang, Y.; Huang, W.; Zhang, L.; Qi, W.; Sun, X.; Li, B.; Xiang, Z.; Ma, C.; Xu, J.; Deng, H.; Li, Y.; Li, P.; Miao, H.; Han, J.; Liu, Y.; Shen, J.; Yu, Y. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles J. Med. Chem. 2014, 57, 9889-9900 10.1021/jm5014659
10. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D. H.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 2000, 43, 1380-1397 10.1021/jm990482t
11. Sequist, L. V.; Besse, B.; Lynch, T. J.; Miller, V. A.; Wong, K. K.; Gitlitz, B.; Eaton, K.; Zacharchuk, C.; Freyman, A.; Powell, C.; Ananthakrishnan, R.; Quinn, S.; Soria, J.-C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 2010, 28, 3076-3083 10.1200/JCO.2009.27.9414
12. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the Her-2 tyrosine kinase Cancer Res. 2004, 64, 3958-3965 10.1158/0008-5472.CAN-03-2868
13. Reckamp, K. L.; Giaccone, G.; Camidge, D. R.; Gadgeel, S. M.; Khuri, F. R.; Engelman, J. A.; Koczywas, M.; Rajan, A.; Campbell, A. K.; Gernhardt, D.; Ruiz-Garcia, A.; Letrent, S.; Liang, J.; Taylor, I.; O'Connell, J. P.; Jänne, P. A. A Phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib Cancer 2014, 120, 1145-1154 10.1002/cncr.28561
14. Dungo, R. T.; Keating, G. M. Afatinib: first global approval Drugs 2013, 73, 1503-1515 10.1007/s40265-013-0111-6
15. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.-H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K.-K.; Eck, M. J.; Gray, N. S.; Jänne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074 10.1038/nature08622
16. Walter, A. O.; Sjin, R. T. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M.; Zhu, Z.; Wang, Z.; Sheets, M.; St. Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC Cancer Discovery 2013, 3, 1404-1415 10.1158/2159-8290.CD-13-0314
17. Cross, D. A. E.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R. V.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Brewer, M. R.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H. P.; Cantarini, M.; Kim, D.-W.; Ranson, M. R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discovery 2014, 4, 1046-1061 10.1158/2159-8290.CD-14-0337
18. Finlay, M. R. V.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A. E.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares wild type form of the receptor J. Med. Chem. 2014, 57, 8249-8267 10.1021/jm500973a
19. For an account on the research leading up to the discovery of AZD-9291, see: Ward, R. A.; Anderton, M. J.; Ashton, S.; Bethel, P. A.; Box, M.; Butterworth, S.; Colclough, N.; Chorley, C. G.; Chuaqui, C.; Cross, D. A. E.; Dakin, L. A.; Debreczeni, J. E.; Eberlein, C.; Finlay, M. R. V.; Hill, G. B.; Grist, M.; Klinowska, T. C. M.; Lane, C.; Martin, S.; Orme, J. P.; Smith, P.; Wang, F.; Waring, M. J. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) J. Med. Chem. 2013, 56, 7025-7048 10.1021/jm400822z
20. It should be noted that there has also been an effort on the development of reversible EGFRT790M selective inhibitors; see for example: Lee, H.-J.; Schaefer, G.; Heffron, T. P.; Shao, L.; Ye, X.; Sideris, S.; Malek, S.; Chan, E.; Merchant, M.; La, H.; Ubhayakar, S.; Yauch, R. L.; Pirazzoli, V.; Politi, K.; Settleman, J. Noncovalent Wild-type-sparing inhibitors of EGFR T790M Cancer Discovery 2013, 3, 168-181 10.1158/2159-8290.CD-12-0357
21. Sogabe, S.; Kawakita, Y.; Igaki, S.; Iwata, H.; Miki, H.; Cary, D. R.; Takagi, T.; Takagi, S.; Ohta, Y.; Ishikawa, T. Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors ACS Med. Chem. Lett. 2013, 4, 201-205 10.1021/ml300327z
22. Hanan, E. J.; Eigenbrot, C.; Bryan, M. C.; Burdick, D. J.; Chan, B. K.; Chen, Y.; Dotson, J.; Heald, R. A.; Jackson, P. S.; La, H.; Lainchbury, M. D.; Malek, S.; Purkey, H. E.; Schaefer, G.; Schmidt, S.; Seward, E. M.; Sideris, S.; Tam, C.; Wang, S.; Yeap, S. K.; Yen, I.; Yin, J.; Yu, C.; Zilberleyb, I.; Heffron, T. P. Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation J. Med. Chem. 2014, 57, 10176-10191 10.1021/jm501578n
23. Pettus, L. H.; Wurz, R. P.; Xu, S.; Herberich, B.; Henkle, B.; Liu, Q.; McBride, H. J.; Mu, S.; Plant, M. H.; Saris, C. J. M.; Sherman, L.; Wong, L. M.; Chmait, S.; Lee, M. R.; Mohr, C.; Hsieh, F.; Tasker, A. S. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38α mitogen-activated protein kinase J. Med. Chem. 2010, 53, 2973-2985 10.1021/jm100095x
24. Wurz, R. P.; Pettus, L. H.; Xu, S.; Henkle, B.; Sherman, L.; Plant, M.; Miner, K.; McBride, H.; Wong, L. M.; Saris, C. J. M.; Lee, M. R.; Chmait, S.; Mohr, C.; Hsieh, F.; Tasker, A. S. Part 1: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase Bioorg. Med. Chem. Lett. 2009, 19, 4724-4728 10.1016/j.bmcl.2009.06.058
25. Chang, S.; Zhang, L.; Xu, S.; Luo, J.; Lu, X.; Zhang, Z.; Xu, T.; Liu, Y.; Tu, Z.; Xu, Y.; Ren, X.; Geng, M.; Ding, J.; Pei, D.; Ding, K. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 methionine790 mutant J. Med. Chem. 2012, 55, 2711-2723 10.1021/jm201591k
26. Xu, S.; Xu, T.; Zhang, L.; Zhang, Z.; Luo, J.; Liu, Y.; Lu, X.; Tu, Z.; Ren, X.; Ding, K. Design, synthesis and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties J. Med. Chem. 2013, 56, 8803-8813 10.1021/jm4012388
27. Xu, T.; Zhang, L.; Xu, S.; Yang, C.-Y.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, S.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K. Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants Angew. Chem., Int. Ed. 2013, 52, 8387-8390 10.1002/anie.201302313
28. Zhou, W.; Liu, X.; Tu, Z.; Zhang, L.; Ku, X.; Bai, F.; Zhao, Z.; Xu, Y.; Ding, K.; Li, H. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant J. Med. Chem. 2013, 56, 7821-7837 10.1021/jm401045n
29. Wurz, R.; Tasker, A.; Tadesse, S.; Pettus, L. H.; Nguyen, T. T.; Hong, F.-T.; Herberich, B. J.; Harrington, E.; Chen, J. J.; Brown, J. Substituted 7-oxo-pyrido[2,3-d]pyrimidines and their use for the treatment of EGFR/ERBB2 related disorders. Patent application: WO 2014/134308, 2014.
30. For related work see: Ding, K.; Xu, T.; Ding, F.; Zhang, L.; Lu, X.; Li, W.; Ding, J.; Geng, M. 7-Oxo-pyridopyrimidine derivatives, pharmaceutical compositions and uses thereof. Patent application: WO 2014/079232, 2014.
31. Apsunde, T.; Wurz, R. P. Pyridin-2-one synthesis using ester enolates and aryl aminoaldehydes and ketones J. Org. Chem. 2014, 79, 3260-3266 10.1021/jo500284n
32. See for example: Gowan, S. M.; Hardcastle, A.; Hallsworth, A. E.; Valenti, M. R.; Hunter, L.-J. K.; de Haven Brandon, A. K.; Garrett, M. D.; Raynaud, F.; Workman, P.; Aherne, W.; Eccles, S. A. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts Assay Drug Dev. Technol. 2007, 5, 391-401 10.1089/adt.2006.044
33. The KM[ATP] values for EGFRWT, EGFRT790M, EGFRL858R, and EGFRT790M/L858R are 5.2, 5.9, 148, and 8.4 ΜM, respectively; see: Yun, C.-H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K.-K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2070-2075 10.1073/pnas.0709662105
34. For a discussion on preclinical ADME properties of 10 clinically late stage or marketed covalent inhibitors, see: Moghaddam, M. F.; Tang, Y.; ÓBrien, Z.; Richardson, S. J.; Bacolod, M.; Chaturedi, P.; Apuy, J.; Kulkarni, A. A proposed screening paradigm for discovery of covalent inhibitor drugs Drug Metab. Lett. 2014, 8, 19-30 10.2174/1872312808666140317151735
35. For a discussion on reactivity of acrylamides with glutathione, see: Naven, R. T.; Kantesaria, S.; Nadanaciva, S.; Schroeter, T.; Leach, K. L. High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds Toxicol. Res. 2013, 2, 235-244 10.1039/c3tx50027f